Pfizer Q3 2025 Results: Resilience, Innovation and Strategic Focus
Pfizer reported $16.7 billion in revenue for Q3 2025, representing a 6% decline vs. the prior year and a 7% operational drop.
Despite the top-line dip, the company’s Adjusted diluted EPS came in at $0.87, down 18% from the prior year but ahead of many market expectations.
Key Highlights
- The non-COVID biopharma portfolio grew 4% operationally, reflecting strong demand for key franchises.
- Some standout products included: Eliquis: up roughly 22% globally.
- Nurtec ODT/Vydura: up 22% globally.
Meanwhile, pandemic-era leaders saw steep declines:
- Paxlovid: –55% operationally.
- Comirnaty: –20% operationally.
Strategic Signals & Guidance
- Pfizer reaffirmed its full-year 2025 revenue guidance at $61 billion to $64 billion.
- The company raised and narrowed its adjusted EPS guidance to $3.00-$3.15, signalling confidence in its cost management and pipeline.
- Capital allocation and cost-savings remain priorities: multibillion-dollar R&D investments and productivity programs are underway.
Why It Matters
- In a post-COVID era, the decline in vaccine/antiviral revenues is expected, but Pfizer’s ability to grow its non-COVID portfolio highlights its diversification strategy.
- The performance underscores the importance of innovation, product lifecycle management, and clear strategic direction.
- For investors, partners and life-science stakeholders, Pfizer’s results send a message: It’s shifting gears into sustainable growth beyond pandemic products.
Contact:
✉️ Robert Green - +44 (0) 207 863 7302 (ext 802)
✉️ Daniel Bishop - +44 (0) 207 863 7302 (ext 804)
✉️ Shannon Taylor - 857 400 7901 (ext 810)
🌐 Explore more about us on our Website!
📸 Get a closer look at our company culture, team, and daily life on Instagram!